Mode
Text Size
Log in / Sign up
Phase 1 Completed N=6 Basic Science

Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers

Healthy Volunteers
Source: ClinicalTrials.gov NCT01786876 ↗
Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcomePrimary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-002358 — 43476 pg*h/ml

Summary

Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C] SPD557 in healthy male volunteers aged 18 to 50 years (inclusive).The purpose of this study is to investigate how and how quickly SPD557 or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-002358
43476
PRIMARY
Maximum Plasma Concentration (Cmax) of Radiolabelled SSP-002358
4643
PRIMARY
Time to Maximum Plasma Concentration (Tmax) of Radiolabelled SSP-002358
1.25
PRIMARY
Plasma Half-Life (T1/2) of Radiolabelled SSP-002358
11.0
PRIMARY
AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled SSP-002358
101960
PRIMARY
Cmax Whole Blood Total Radioactivity of Radiolabelled SSP-002358
9252
PRIMARY
Tmax Whole Blood Total Radioactivity of Radiolabelled SSP-002358
2.00
PRIMARY
Half-Life Whole Blood Total Radioactivity of Radiolabelled SSP-002358
6.96
PRIMARY
AUC 0→∞ Plasma Total Radioactivity of Radiolabelled SSP-002358
137314
PRIMARY
Cmax Plasma Total Radioactivity of Radiolabelled SSP-002358
11658
PRIMARY
Tmax Plasma Total Radioactivity of Radiolabelled SSP-002358
1.50
PRIMARY
Half-Life Plasma Total Radioactivity of Radiolabelled SSP-002358
10.9
PRIMARY
Percent Total Radioactivity Excreted in Urine of Radiolabelled SSP-002358
38.2
PRIMARY
Percent Total Radioactivity Excreted in Stool of Radiolabelled SSP-002358
57.3

Eligibility Criteria

Key Inclusion Criteria

  • Males ages 18 to 50 years
  • Have a body mass index (BMI) of ≥18.5 and ≤30 kg/m2
  • Subject is willing to comply with any applicable contraceptive and sperm donation requirements

Key Exclusion criteria

  • Have participated in a [14C]-study within the last 6 months.
  • Exposure to clinically significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring).
  • Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
  • Subjects who report typically having more than 2 bowel movements per day, less than 3 bowel movements per week or those whose bowel habits have changed significantly within 30 days
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01786876). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search